Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring
Provided By GlobeNewswire
Last update: Jan 27, 2025
– AK006 did not demonstrate therapeutic activity in CSU –
– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –
– Management to host conference call and webcast today at 8:30 am E.T. –
